You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Targeted Polymer Micelles for Treatment of Metastatic Melanoma
SBC: INTEZYNE TECHNOLOGIES, INC. Topic: NCIDESCRIPTION (provided by applicant): According to the American Cancer Society, half of all men and one-third of all women in the United States will develop cancer in their lifetime. While chemotherapy has dramatically improved the survival rate of cancer patients, it comes at the cost of severe toxicities and in some cases poor response rates. In order to address these shortcomings, equal investme ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
The anti-tumorigenic and anti-metastatic potential of Eya phosphatase inhibitors
SBC: SIXONE SOLUTIONS, LLC Topic: NCIDESCRIPTION (provided by applicant): Breast cancer is expected to cause 39,510 deaths of American women in 2012 and 450,000 deaths globally. Once breast cancer has spread, it is essentially incurable. A critical barrier to treating advanced breast cancer is the lack of cancer-specific drugs that are effective in a large percentage of cancer patients and have low toxicity. Sixone Solutions, LLC pro ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Live-Cell Fluorescence Lifetime FRET Assays for HTS
SBC: Fluorescence Innovations, Inc. Topic: NIDADESCRIPTION (provided by applicant): This project will establish proof-of-concept for a powerful and versatile implementation of live-cell assays in a true high-throughput screening (HTS) format for small-molecule drug discovery. The technological basis isfluorescence lifetime (FLT) readout of FRET between fluorescent fusion proteins. Lifetime measurement is needed in HTS to overcome the low preci ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Screens for Novel Agonists/Antagonists of Endocrine Fibroblast Growth Factors
SBC: AGAVE BIOSYSTEMS INC. Topic: NIDDKDESCRIPTION (provided by applicant): Agave BioSystems and Professor Makoto Kuro-o at the University of Texas Southwestern Medical Center are proposing a collaborative effort to screen for novel small molecules acting as agonists or antagonists of the Klotho and Klotho- dependent endocrine Fibroblast Growth Factors. The expected outcome of this Phase I effort will be the validation of a high-throug ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Preclinical Efficacy And Safety Evaluation Of Graphene Nanoparticle-based Magneti
SBC: Theragnostic Technologies Inc. Topic: NIDDKAbstract This STTR phase 1 proposal investigates the safety and efficacy of a novel high-performance carbon nanostructure-based magnetic resonance imaging (MRI) contrast agent for the imaging and monitoring of patients with renal failure. Every year, in the US, approximately 20 million people are treated for mild to severe renal failure. A significant number of cases (greater than 50%) related to ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
In-situ, real-time oxygen sensor to monitor the long-term efficacy of aerobicall
SBC: ChromoSense LLC Topic: NIEHSDESCRIPTION (provided by applicant): Groundwater and soil contamination has been associated with higher incidence of birth defects and cancer. Monitored natural attenuation of contaminants via biodegradation has proven effective in lowering contaminant levels, but these processes depend critically on dissolved oxygen levels. This project proposes to develop a robust oxygen sensor compound with che ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Zonular Capture Accommodative-Disaccommodative Intraocular Lens System
SBC: Z Lens LLC Topic: NEIDESCRIPTION (provided by applicant): We are developing an accommodative - disaccommodative intraocular lens implant (ADIOL) system based on a novel concept of capturing zonular tension and transmitting it unimpeded to a dynamically position intraocular lens system. This is made possible by a zonular capture haptic (ZCH) apparatus. This apparatus lends itself equally well to several possible combin ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Innovative Use of the Noom Monitor Mobile Application for CBT-GSH in Binge Eaters
SBC: Noom, Inc. Topic: NIMHDESCRIPTION (provided by applicant): Bulimia nervosa and binge eating disorder are marked by significant levels of impairment and psychiatric comorbidity, affecting approximately 5-7% of the US population. Guided self-help cognitive behavioral (CBT-GSH) therapy has been show to be an effective treatment to reduce binge eating for patient with both disorders. However, there is limited uptake among ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Remote focusing through spatial light modulation for multifocal multiphoton micro
SBC: BOULDER NONLINEAR SYSTEMS, INC. Topic: NIMHDESCRIPTION (provided by applicant): Nonlinear optical microscopy techniques (such as two-photon florescence) are being used to acquire volumetric (i.e. three dimensional) images that probe several hundred microns into scattering tissue. These techniques are being combined with fast acquisition schemes to allow imaging of live, moving specimens at high NA. This combination allows for high-resoluti ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Neurorestorative therapy of stroke with HUCBC in T2DM rats
SBC: SANERON CCEL THERAPEUTICS, INC. Topic: NINDSDESCRIPTION (provided by applicant): Diabetes mellitus (DM) leads to a 3-4 fold higher risk of experiencing ischemic stroke. In addition, DM stroke patients are more prone to develop more and earlier white matter (WM) high-intensity lesions than non DM stroke patients. Treatment of stroke with tissue plasminogen activator (rtPA) at 2-3 hours after stroke decreases lesion volume in non-DM rats. How ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health